Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
111 Inc (YI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: YI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.17% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.15M USD | Price to earnings Ratio - | 1Y Target Price 5.96 |
Price to earnings Ratio - | 1Y Target Price 5.96 | ||
Volume (30-day avg) 33258 | Beta 0.39 | 52 Weeks Range 4.14 - 14.10 | Updated Date 03/30/2025 |
52 Weeks Range 4.14 - 14.10 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate - | Actual -0.3195 |
Profitability
Profit Margin -2.25% | Operating Margin (TTM) 0.1% |
Management Effectiveness
Return on Assets (TTM) -5.99% | Return on Equity (TTM) -66.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 39652691 | Price to Sales(TTM) 0.01 |
Enterprise Value 39652691 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 37.65 | Shares Outstanding 49664300 | Shares Floating 68617082 |
Shares Outstanding 49664300 | Shares Floating 68617082 | ||
Percent Insiders 16.16 | Percent Institutions 23.89 |
Analyst Ratings
Rating - | Target Price 5.96 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
111 Inc
Company Overview
History and Background
111, Inc. was founded in 2010 and is headquartered in Shanghai, China. It operates as an integrated online and offline platform in China, providing pharmaceutical products and healthcare services. It initially focused on online retail of pharmaceutical products and has since expanded into offline pharmacies and online medical consultation.
Core Business Areas
- B2C Online Pharmacy: Operates Yihaodian Yaofang, an online retail pharmacy platform selling prescription drugs, OTC medications, nutritional supplements, medical devices, and other healthcare products.
- B2B Pharmaceutical Distribution: Provides pharmaceutical distribution services to pharmacies and other healthcare providers through its Yaofang Wang platform.
- Online Medical Consultation: Offers online consultation services through its 1 Clinic platform, connecting patients with doctors for diagnosis and prescription refills.
- Retail Pharmacy Network: Manages a network of retail pharmacies under the 1 Drugstore brand, providing offline access to medications and healthcare services.
Leadership and Structure
The CEO is Gang Yu. The company has a typical corporate structure with a board of directors and executive management team overseeing various functional departments.
Top Products and Market Share
Key Offerings
- Prescription Drugs: A significant portion of 111 Inc's revenue comes from prescription drug sales through its online and offline channels. Market share data for online prescription drug sales in China is fragmented, with several players competing. Competitors include Alibaba Health (AHGZF) and JD Health (JDHIF).
- OTC Medications: Over-the-counter medications are another key product category. Similar to prescription drugs, the OTC market is competitive. Competitors include traditional pharmacies and other online retailers.
- Nutritional Supplements: Sales of vitamins and nutritional supplements contribute to the company's revenue. Competitors include health supplement companies and e-commerce platforms.
- Medical Devices: The company sales medical devices through their online platform and has some market share in this segment. Competitors include other companies like Medtronic (MDT) and Abbott (ABT).
Market Dynamics
Industry Overview
The Chinese pharmaceutical market is large and growing, driven by an aging population, increasing healthcare awareness, and government support for the healthcare industry. The market is undergoing digital transformation with increasing adoption of online pharmacies and telemedicine services.
Positioning
111 Inc is positioned as an integrated online and offline healthcare platform. Its competitive advantages include its established online presence, extensive product offerings, and partnerships with pharmaceutical manufacturers and distributors.
Total Addressable Market (TAM)
The Chinese pharmaceutical market is estimated to be several hundred billion USD annually. 111 Inc is positioned to capture a significant share of this market through its online and offline platforms, though its actual penetration remains relatively small.
Upturn SWOT Analysis
Strengths
- Integrated online and offline platform
- Extensive product offerings
- Strategic partnerships
- Established brand recognition
Weaknesses
- High operating expenses
- Dependence on regulatory approvals
- Competition from larger players
- Profitability challenges
Opportunities
- Growing demand for online healthcare services
- Expansion into new geographic markets
- Development of new healthcare products and services
- Increasing government support for the healthcare industry
Threats
- Changing regulations
- Increased competition
- Price pressures
- Economic slowdown in China
Competitors and Market Share
Key Competitors
- AHGZF
- JDHIF
Competitive Landscape
111 Inc faces intense competition from larger players with greater resources and established brand recognition. Its advantages include its integrated platform and focus on the online healthcare market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: 111 Inc has experienced rapid revenue growth in recent years, driven by the expansion of its online and offline platforms.
Future Projections: Analysts project continued revenue growth for 111 Inc, but profitability remains a key challenge.
Recent Initiatives: Recent initiatives include expanding its retail pharmacy network, developing new online healthcare services, and strengthening partnerships with pharmaceutical companies.
Summary
111 Inc is a growing integrated online and offline healthcare platform in China. It has shown revenue growth but is still working on profitability. Its strengths include an established online presence, extensive product offerings, and partnerships, while its weaknesses involve high operating costs and strong competition. Continued expansion and effective cost management are crucial for its success.
Similar Companies
AMZN
Amazon.com Inc
AMZN
Amazon.com Inc
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is based on available estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 111 Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-09-12 | Co-Founder, Acting CFO, Chairman & CEO Mr. Junling Liu | ||
Sector Healthcare | Industry Medical Distribution | Full time employees - | Website https://corporate.111.com.cn |
Full time employees - | Website https://corporate.111.com.cn | ||
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, sexual wellness products, and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. In addition, it offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. The company operates offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangdong, Guangzhou, Tianjin, and Kunshan. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.